EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR-INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): FINAL SAFETY ANALYSIS OF 117 CHINESE CML PATIENTS

被引：0
|
作者：
Shen, Z. [1 ]
Huang, X. [2 ]
Meng, F. [3 ]
Wang, J. [4 ,5 ,8 ]
Liu, T. [6 ]
Hu, J. [7 ]
Wang, J. [4 ,5 ,8 ]
Zhao, Y. [9 ]
Woodman, R. [8 ]
Zou, P. [10 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China
[2] Beijing Univ, Beijing 100871, Peoples R China
[3] Nanfang Med Univ, Guangzhou, Guangdong, Peoples R China
[4] Chinese Acad Med Sci, Tianjin, Peoples R China
[5] Peking Union Med Coll, Tianjin, Peoples R China
[6] Sichuan Univ, Chengdu 610064, Peoples R China
[7] Fujian Med Univ, Affiliated Union Hosp, Fuzhou, Fujian, Peoples R China
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharmaceut Co Ltd, Beijing, Peoples R China
[10] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan 430074, Peoples R China
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0865
引用
收藏
页码：348 / 349
页数：2
相关论文
共 50 条
  • [1] EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): UPDATED SAFETY ANALYSIS
    Nicolini, F.
    Alimena, G.
    Shen, Z.
    Al-Ali, H. -K
    Turkina, A.
    Smith, G.
    Pasquini, R.
    Jootar, S.
    Hsu, Y.
    Veronese, M. L.
    Powell, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 53 - 53
  • [2] FINAL SAFETY ANALYSIS OF 1,793 CML PATIENTS FROM ENACT (EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA
    Nicolini, F. E.
    Alimena, G.
    Al-Ali, H. K.
    Turkina, A. T.
    Shen, Z.
    Jootar, S.
    Smith, G.
    De Souza, C.
    Wang, J.
    Berton, M.
    Szczudlo, T.
    Rizzieri, D. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 255 - 256
  • [3] Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study
    le Coutre, Philipp D.
    Turkina, Anna
    Kim, Dong-Wook
    Ceglarek, Bernadeta
    Alimena, Giuliana
    Al-Ali, Haifa Kathrin
    Shen, Zhixiang
    Jootar, Saengsuree
    Smith, Graeme
    De Souza, Carmino Antonio
    Dorlhiac-Llacer, Pedro Enrique
    Rizzieri, David A.
    Szczudlo, Tomasz
    Berton, Myriam
    Wang, Jim
    Wang, Si-Tien
    Nicolini, Franck Emmanuel
    BLOOD, 2009, 114 (22) : 1272 - 1273
  • [4] EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS (PTS) WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): SUBGROUP ANALYSIS OF PATIENTS WHO FAILED PRIOR DASATINIB THERAPY
    Nicolini, F. E.
    Alimena, G.
    Al-Ali, H. K.
    Turkina, A. T.
    Shen, Z.
    Jootar, S.
    Smith, G.
    Conchon, M.
    Wang, J.
    Berton, M.
    Szczudlo, T.
    Rizzieri, D. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 257 - 257
  • [5] Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.
    le Coutre, Philipp D.
    Ceglarek, Bernadeta
    Turkina, Anna
    Kim, Dong-Wook
    Alimena, Giuliana
    Al-Ali, Haifa Kathrin
    Shen, Zhixiang
    Jootar, Saengsuree
    Smith, Graeme
    De Souza, Carmino Antonio
    Rizzieri, David A.
    Szczudlo, Tomasz
    Berton, Myriam
    Wang, Jim
    Dial, Ellison
    Nicolini, Franck Emmanuel
    BLOOD, 2009, 114 (22) : 457 - 458
  • [6] ENACT (Expanding Nilotinib Access in Clinical Trials) study in adult patients (pts) with Imatinib-resistant or - intolerant Chronic Myeloid Leukemia (CML): Subgroup analysis of Pts from Germany, Austria and Switzerland (DACH)
    Al-Ali, H. K.
    le Coutre, P.
    Duyster, J.
    Linkesch, W.
    Wolf, D.
    Schanz, U.
    Baerlocher, G. M.
    Wackwitz, B.
    Heim, D.
    ONKOLOGIE, 2011, 34 : 267 - 267
  • [7] Expanding nilotinib access in clinical trials (ENACT) study in adult patients (Pts) with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in blast crisis (BC), accelerated phase (AP), or chronic phase (CP): Preliminary safety analysis
    Nicolini, Franck
    Alimena, Giuliana
    Al-Ali, Haifa-Kathrin
    Zaritskey, Andrey
    Shen, Zhixiang
    Jootar, Saengsuree
    Smith, Graeme
    Hsu, Yanzhi
    Veronese, Maria Luisa
    Rizzieri, David A.
    BLOOD, 2007, 110 (11) : 870A - 870A
  • [8] NILOTINIB SAFETY AND RESPONSES ANALYSIS IN RUSSIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) FROM ENACT(EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS) STUDY
    Turkina, A.
    Khoroshko, N.
    Bakirov, A.
    Korobkin, A.
    Pospelova, T.
    Rossiev, V.
    Shatokhin, Y.
    Silin, A.
    Zaritsky, A.
    Kravchenko, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 534 - 534
  • [9] Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)
    Giles, Francis J.
    Yin, Ophelia
    Chia, Yen Lin
    le Coutre, Philipp D.
    Woodman, Richard C.
    Ottmann, Oliver G.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 390 - 390
  • [10] NILOTINIB IS ACTIVE IN IMATINIB RESISTANT AND INTOLERANT CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Koren-Michowitz, M. K. M.
    Le Coutre, P.
    Duyster, J.
    Scheid, C.
    Rowe, J. M.
    Goldschmidt, N.
    Ribakovsky, E.
    Nagler, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 222 - 223
12345